| Patents for C07K 16 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies (149,320) |
|---|
| 03/11/2010 | WO2010027364A1 Anti-extended type i glycosphingolipid antibody, derivatives thereof and use |
| 03/11/2010 | WO2010027029A1 Temperature-responsive magnetic fine grains capable of freeze drying |
| 03/11/2010 | WO2010026758A1 Monoclonal antibody, and immunoassay using same |
| 03/11/2010 | WO2010026489A1 Innate immunity modulators |
| 03/11/2010 | WO2010026473A2 Pta072 protein |
| 03/11/2010 | WO2010026291A1 Materials and methods for inhibiting cancer cell invasion related to fgfr4 |
| 03/11/2010 | WO2010025541A1 Identification of a conserved inner core oligosaccharide region of moraxella catarrhalis lipopolysaccharide as a vaccine antigen |
| 03/11/2010 | WO2010007144A3 Mutated netrin-4 proteins, fragments thereof and their uses as drugs |
| 03/11/2010 | WO2010004438A3 Lm-antibodies, functional fragments, lm-1 target antigen, and methods for making and using same |
| 03/11/2010 | WO2010001251A3 Camelid derived antigen binding polypeptides |
| 03/11/2010 | WO2009143472A3 Method of generating single vl domain antibodies in transgenic animals |
| 03/11/2010 | US20100063260 Whitefly Ecdysone Receptor Antibody |
| 03/11/2010 | US20100063259 Compositions and methods for diagnosing or treating psoriasis |
| 03/11/2010 | US20100063258 Fusion protein constructs |
| 03/11/2010 | US20100063257 Purification of FC-TACI Fusion Proteins Using the Oilbody Technology |
| 03/11/2010 | US20100063130 Method for promoting immune response comprising inhibiting cd22 function in b cells |
| 03/11/2010 | US20100062977 TCR-Independent Activation of T Cells |
| 03/11/2010 | US20100062542 Antibody against aflatoxins, support using the antibody, method of immunologically detecting aflatoxins and method of concentrating and purifying aflatoxins |
| 03/11/2010 | US20100062514 Rearranged squamous cell carcinoma antigen genes ii |
| 03/11/2010 | US20100062487 Novel genes encoding proteins having prognostic, diagnostic, preventive, therapeutic, and other uses |
| 03/11/2010 | US20100062462 Immunodeficiency viruses |
| 03/11/2010 | US20100062457 Biomarkers, kits, and method for diagnosing, monitoring, and/or staging alzheimer's disease |
| 03/11/2010 | US20100062456 Using g protein coupled receptor to identify modulators of taste signal transduction; generating of taste topographic maps that elucidate relationship between taste cells of tongue and taste sensory neurons in brain |
| 03/11/2010 | US20100062453 Method of diagnosing endometriosis in human subjects |
| 03/11/2010 | US20100062449 Method Of Measuring PTX3 With High Sensitivity |
| 03/11/2010 | US20100062440 markers for cancer |
| 03/11/2010 | US20100062038 Markers, Antibodies and Recombinant scFvs for Mesenchymal Stem Cell Sub-populations and Osteoclasts |
| 03/11/2010 | US20100062022 Immunogenic proteins of burkholderia pseudomallei and uses thereof |
| 03/11/2010 | US20100062016 Microorganisms for therapy |
| 03/11/2010 | US20100062013 Cancer antigen peptides derived from wt1 |
| 03/11/2010 | US20100062010 Novel peptide compound |
| 03/11/2010 | US20100062008 Drug conjugates and their use for treating cancer, an autoimmune disease or an infectious disease |
| 03/11/2010 | US20100062006 Treatment of stomach cancer with steroid compounds and precipitation |
| 03/11/2010 | US20100062005 Methods and Compounds for Lymphoma Cell Detection and Isolation |
| 03/11/2010 | US20100062004 Amino acid sequences directed against gpcrs and polypeptides comprising the same for the treatment of gpcr-related diseases and disorders |
| 03/11/2010 | US20100062003 Therapeutic and diagnostic applications based on the role of the cxcr-4 gene in tumorigenesis |
| 03/11/2010 | US20100062001 Antibodies for selective apoptosis of cells |
| 03/11/2010 | US20100061999 Antihuman tnf-alpha antibody activity lowering inhibitor |
| 03/11/2010 | US20100061998 Il-1beta binding antibodies and fragments thereof |
| 03/11/2010 | US20100061996 Methods and compositions for modulating hepsin activation of urokinase-type plasminogen activator |
| 03/11/2010 | US20100061993 Antibodies |
| 03/11/2010 | US20100061988 Monoclonal antibodies |
| 03/11/2010 | US20100061987 High Affinity Antibodies Against HMGB1 and Methods Of Use Thereof |
| 03/11/2010 | US20100061986 Chronic Rejection Inhibitor |
| 03/11/2010 | US20100061985 Antagonists of tweak and of tweak receptor and their use to treat immunological disorders |
| 03/11/2010 | US20100061979 Modified soluble fgf receptor fc fusions wsith improved biological activity |
| 03/11/2010 | US20100061977 Methods and compositions for treating and diagnosing diseases |
| 03/11/2010 | US20100061973 Graded Expression of Snail as Marker of Cancer Development and DNA Damage-Based Diseases |
| 03/11/2010 | US20100061933 Pharmaceutical composition comprising anti-hb-egf antibody as active ingredient |
| 03/11/2010 | DE102008045815A1 Combination of an antibody and a bacterium, which expresses Fc-receptors or proteins, which bind the light chain of an antibody, useful for the treatment of tumors and their precursors, preferably colorectal carcinoma |
| 03/11/2010 | CA2738034A1 Materials and methods for inhibiting cancer cell invasion related to fgfr4 |
| 03/11/2010 | CA2736799A1 Conserved hemagglutinin epitope, antibodies to the epitope, and methods of use |
| 03/11/2010 | CA2735433A1 Anti-extended type i glycosphingolipid antibody, derivatives thereof and use |
| 03/11/2010 | CA2735193A1 T-cell receptor antibodies and methods of use thereof |
| 03/11/2010 | CA2734919A1 Lyophilized formulatons of engineered anti-il-23p19 antibodies |
| 03/11/2010 | CA2734905A1 Multispecific antibodies |
| 03/11/2010 | CA2734704A1 Monoclonal antibody and immunoassay using the same |
| 03/11/2010 | CA2733943A1 Peptides presenting an epitope of an a domain of factor h binding protein and methods of use |
| 03/11/2010 | CA2732338A1 Identification of a conserved inner core oligosaccharide region of moraxella catarrhalis lipopolysaccharide as a vaccine antigen |
| 03/10/2010 | EP2161578A1 Proteins in diabetes proteome analysis |
| 03/10/2010 | EP2161338A1 Isolated mammalian monocyte cell genes; related reagents |
| 03/10/2010 | EP2161336A1 Human monoclonal antibodies to programmed death 1(PD-1) and methods for treating cancer using anti-PD-1 antibodies alone or in combination with other immunotherapeutics |
| 03/10/2010 | EP2161335A1 NOVEL GPIIIa GENE |
| 03/10/2010 | EP2161286A1 Antibodies |
| 03/10/2010 | EP2161285A1 Monoclonal antibodies for neutralizing anthrax toxin |
| 03/10/2010 | EP2161283A1 Compositions comprising antibodies against CD79b conjugated to a growth inhibitory agent or cytotoxic agent and methods for the treatment of tumor of hematopoietic origin |
| 03/10/2010 | EP2161280A2 Genes involved in the regulation of angiogenesis, pharmaceutical preparations containing them and their applications |
| 03/10/2010 | EP2160601A1 Method for predicting the response of a patient to treatment with an anti-tnf alpha antibody |
| 03/10/2010 | EP2160411A1 Anti-vpac1 antibodies and their uses |
| 03/10/2010 | EP2160410A1 Induction of tolerogenic phenotype in mature dendritic cells |
| 03/10/2010 | EP2160409A1 Amino acid sequences directed against growth factor receptors and polypeptides comprising the same for the treatment of diseases and disorders associated with growth factors and their receptors |
| 03/10/2010 | EP2160407A1 Neutralizing antibodies |
| 03/10/2010 | EP2160406A1 Antibodies useful for therapy and diagnosis of cancer |
| 03/10/2010 | EP2160405A2 Expression of soluble antibody fragment by truncation of ch1 domain |
| 03/10/2010 | EP2160403A1 Methods of producing a secreted protein |
| 03/10/2010 | EP1544293B1 Antibody against enzyme specifically cleaving von villebrand factor and assay system using the same |
| 03/10/2010 | EP0932678B2 A family of genes encoding apoptosis-related peptides, peptides encoded thereby and methods of use thereof |
| 03/10/2010 | EP0830146B1 Methods of inducing immune tolerance using immunotoxins |
| 03/10/2010 | CN101668776A Antagonist ox40 antibodies and their use in the treatment of inflammatory and autoimmune diseases |
| 03/10/2010 | CN101668775A Use of il-23 antagonists for treatment of infection |
| 03/10/2010 | CN101668774A Anti-ip-10 antibodies and methods of use thereof |
| 03/10/2010 | CN101668773A humaneered anti-factor b antibody |
| 03/10/2010 | CN101668772A Activation of human antigen-presenting cells through dendritic cell lectin-like oxidized ldl receptor-1 (lox-1) |
| 03/10/2010 | CN101668771A Sequence based engineering and optimization of single chain antibodies |
| 03/10/2010 | CN101665536A Anti-vegf antibodies |
| 03/10/2010 | CN100593544C Mutants of the P4 protein of nontypable haemophilus influenzae with reduced enzymatic activity |
| 03/09/2010 | US7674888 Viral material and nucleotide fragments associated with multiple sclerosis, for diagnostic, prophylactic and therapeutic purposes |
| 03/09/2010 | US7674884 Neutralizing antibodies and methods of use thereof |
| 03/09/2010 | US7674883 Hybridoma cell line for production of transmembrane protein with EGF-like and 2 follistatin-like domains 2 specific immunoglobulin conjugate for diagnosis and treatment of prostate cancer |
| 03/09/2010 | US7674768 Processes for preparing eptifibatide |
| 03/09/2010 | US7674618 Expression vector |
| 03/09/2010 | US7674604 Using computer modeling to identify positions where cysteinal insertion will lock protein comprising integrin domain sequences into preferential configuration; directed protein evolution |
| 03/09/2010 | US7674599 Methods of using antibodies to detect alpha-synuclein in fluid samples |
| 03/09/2010 | US7674462 Transforming growth factor receptor specific immunoglobulin for use in diagnosis prvention and treatment of tumor disorders; immunotherapy |
| 03/09/2010 | US7674461 Monoclonal antibody to interleukins polypeptide for treating and preventing inflammatory bowel, crohn's, arthritis and psoriasis disorders |
| 03/09/2010 | US7674460 Compositions and methods for restoring sensitivity to treatment with HER2 antagonists |
| 03/09/2010 | US7674459 treatment of Interleukin13 dependent neoplastic disorders; high affinity to both glycosylated and non-glycosylated human IL13; do not bind mouse IL13, and neutralize human IL13 activity at an approximate molar ratio of 1:2 (MAb:IL13) |
| 03/09/2010 | US7674451 Cosmetic or pharmaceutical composition comprising peptides, uses and treatment processes |
| 03/09/2010 | CA2382464C High-affinity choline transporter |
| 03/09/2010 | CA2264963C Protein markers for esophageal cancer |